<DOC>
	<DOCNO>NCT03092245</DOCNO>
	<brief_summary>Efficacy safety OctaplasLG® administration vs. crystalloids ( standard ) patient septic shock - randomize , control , open-label investigator-initiated pilot trial</brief_summary>
	<brief_title>Vasculopathic Injury Plasma Endothelial Rescue Septic Shock ( SHOCK ) Trial</brief_title>
	<detailed_description>This single center , randomize ( 1:1 , active : standard care ) , control , open-label , investigator-initiated pilot phase IIa trial patient septic shock investigate efficacy safety administrate OctaplasLG® compare crystalloids , Ringer-Acetate ( standard care ) total 40 patient . 40 patient enrol : - Patients active treatment group ( n = 20 patient ) receive OctaplasLG® volume support accord trial algorithm . - Patients standard care group ( n = 20 patient ) receive crystalloids , Ringer-Acetate , volume support accord trial algorithm . All patient treat accord standard ICU care .</detailed_description>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<criteria>1 . Adult intensive care patient ( age ≥ 18 year ) AND 2 . Sepsis , define lifethreatening organ dysfunction cause dysregulated host response infection AND 3 . Quick SOFA ( qSOFA ) two 1 . Respiratory rate ≥ 22/min 2 . Altered mentation ( Glasgow Coma Scale score &lt; 15 ) 3 . Systolic blood pressure ≤ 100mmHg AND 4 . Septic shock , define clinical construct sepsis persist hypotension require vasopressor maintain MAP ≥65 mm Hg serum lactate level &gt; 2 mmol/L despite adequate volume resuscitation AND 5 . Requiring infusion noradrenalin 0.10 mcg/kg/min maintain blood pressure AND 6 . Respiratory failure require intubation mechanical ventilation 1 . Documented refusal blood transfusion OR 2 . Treatment GPIIb/IIIa inhibitor &lt; 24h screening OR 3 . Withdrawal active therapy OR 4 . Previously within 30 day include interventional trial OR 5 . Known IgA deficiency document antibody IgA OR 6 . Known hypersensitivity OctaplasLG® : active substance , excipients ( Sodium citrate dihydrate , Sodium dihydrogenphosphate dihydrate Glycine ) residues manufacture process ( Tri ( NButyl ) Phosphate ( TNBP ) Octoxynol ( Triton X100 ) ) OR 7 . Known severe deficiency protein S OR 8 . Pregnancy ( nonpregnancy confirm patient postmenopausal negative urinehCG ) OR 9 . Severe cirrhotic hepatic failure expect need treatment terlipressin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>